Wednesday, 1 April 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 01 April 2026
News

Company responds to sale rumours

 Posted 1 April 2026 AM

Italian pharma Recordati Rare Disease has been forced to respond to swirling speculation that the company is being sold - admitting there is in fact an offer on the table.

In a statement, the company - which is headquartered in Milan but has about 150 offices around the world, including in Australia - said the offer from private equity firm CVC Capital Partners had not yet been reviewed.

To see the whole article, please login

Popular

Pharma unveils a new name
Blockbuster scores triple PBS win
Butler feels chill from big pharma
Studying? Aussie uni smashing it
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home